See more : Econocom Group SE (ECONB.BR) Income Statement Analysis – Financial Results
Complete financial analysis of NLS Pharmaceutics AG (NLSP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NLS Pharmaceutics AG, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Woojin Plaimm Co., Ltd. (049800.KS) Income Statement Analysis – Financial Results
- Unusual Machines, Inc. (UMAC) Income Statement Analysis – Financial Results
- Anhui Liuguo Chemical Co., Ltd. (600470.SS) Income Statement Analysis – Financial Results
- Pedro Resources Ltd. (VBN.CN) Income Statement Analysis – Financial Results
- Euromedis Groupe (ALEMG.PA) Income Statement Analysis – Financial Results
NLS Pharmaceutics AG (NLSP)
About NLS Pharmaceutics AG
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 11.41K | 11.41K | 10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -11.41K | -11.41K | -10.05K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.91M | 8.98M | 5.92M | 99.58K | 1.70M | 1.44M | 4.32M |
| General & Administrative | 5.90M | 6.51K | 5.94K | 2.20K | 3.30M | 2.01M | 1.44M |
| Selling & Marketing | 0.00 | 6.49M | 5.93M | 2.20M | 2.49M | 0.00 | 0.00 |
| SG&A | 5.90M | 6.49M | 5.93M | 2.20M | 2.49M | 2.01M | 1.44M |
| Other Expenses | 0.00 | 10.05K | -17.32K | -328.37K | 0.00 | -629.23K | 0.00 |
| Operating Expenses | 11.81M | 15.47M | 11.85M | 2.30M | 4.20M | 3.45M | 5.77M |
| Cost & Expenses | 11.81M | 15.48M | 11.86M | 2.30M | 4.20M | 3.45M | 5.77M |
| Interest Income | 0.00 | 100.87 | 68.13 | 233.70 | 819.71 | 16.04K | 890.40 |
| Interest Expense | 145.15K | 100.87K | 68.13K | 233.70K | 819.71K | 1.07M | 890.40K |
| Depreciation & Amortization | 11.41K | 11.41K | 10.05K | 2.30M | 4.20M | 3.45M | 5.77M |
| EBITDA | -11.80M | -15.47M | -11.85M | 0.00 | -430.40K | -613.20K | -5.77M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.81M | -15.48M | -11.86M | -2.30M | -4.20M | -3.45M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -364.97K | -1.01M | -85.46K | -562.07K | -1.25M | -1.70M | -890.40K |
| Income Before Tax | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.00 | -226.51K | -2.30K | -4.20K | 1.70M | -5.77K |
| Net Income | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| EPS Diluted | -0.32 | -0.84 | -0.81 | -0.59 | -0.49 | -0.44 | -0.57 |
| Weighted Avg Shares Out | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
| Weighted Avg Shares Out (Dil) | 38.18M | 19.68M | 14.75M | 4.82M | 11.14M | 11.78M | 11.78M |
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
ZURICH, SWITZERLAND / ACCESSWIRE / October 25, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP,NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system...
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
ZURICH, SWITZERLAND / ACCESSWIRE / October 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3, NLS to Webcast its Event Friday, October 20 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / October 12, 2023 / NLS Pharmaceutics Ltd....
NLS Pharmaceutics CEO Issues Letter to Shareholders
ZURICH, SWITZERLAND / ACCESSWIRE / August 28, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
NLS Pharmaceutics shares rise as narcolepsy treatment moves to phase 3 studies
Shares of NLS Pharmaceutics Ltd. NLSP, +19.57% gained 12% premarket on Monday after the Swiss clinical-stage biopharma company said it would proceed with phase 3 clinical studies of Mazindol ER, a treatment for narcolepsy.
NLS Pharmaceutics Company Update and Webcast Today Postponed
NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET ZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Presentation to take place on Tuesday, June 20, 2023, at 10:30AM ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...
NLS Pharmaceutics Announces Company Update Webcast
Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023...
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
ZURICH, SWITZERLAND / ACCESSWIRE / June 15, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous...
NLS Pharmaceutics Announces Company Update Webcast
Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / June 15, 2023...
Source: https://incomestatements.info
Category: Stock Reports